Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Other Medicinal Products for Human Use

Medicines for which the Paul-Ehrlich-Institut is responsible, but which are not assigned to a particular group of medicines.

Search results 26 to 33 from a total of 33

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Uro-Vaxom

lysierte immunaktive Fraktionen aus ausgewählten Escherichia-coli-Stämmen

Anwendung bei rezidivierenden und chronischen Harnwegsinfektionen

OMEDICAMED Unipessoal Lda

weitere 450a/85 11.12.1987

PharmNet.Bund

Uro-Vaxom

Immun­thera­peutikum bei rezi­divieren­den Harnwegs­infektionen

kohlpharma GmbH

 weitere PEI.H.11548.01.1 03.11.2011

Uro-Vaxom

Immun­therapeutikum bei rezidi­vierenden Harnwegs­infektionen

EMRA-MED Arzneimittel GmbH

 weitere PEI.H.11538.01.1 03.11.2011

Uro-Vaxom 6 mg

Immun­thera­peutikum bei rezi­divieren­den Harnwegs­infektionen

Pharma Gerke GmbH

 weitere PEI.H.11524.01.1 02.11.2011

PharmNet.Bund

Uro-Vaxom 6 mg Hartkapseln

Multibacterial Lysat

Immun­therapeutikum bei rezi­divierenden + chronischen Harnwegs­infektionen

EURIM-PHARMA Arzneimittel GmbH

 weitere PEI.H.11451.01.1 26.07.2010

PharmNet.Bund

Uro-Vaxom, 6 mg Hartkapseln

E. coli-Fraktionen

Immun­thera­peutikum bei rezi­divieren­den Harnwegs­infektionen

Orifarm GmbH

 weitere PEI.H.12062.01.1 16.07.2021

Uro-Vaxom, 6mg, Hartkapseln

Immun­therapeutikum bei rezidi­vierenden Harnwegs­infektionen

Abacus Medicine A/S

, DK

 weitere PEI.H.11979.01.1 21.09.2021

Viacituro

Immunstimulans

Therapie des oberflächlichen Harnblasentumors

Medac Gesellschaft für klinische Spezialpräparate mbH

 weitere PEI.H.12227.01.1 16.01.2025

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 528 in BAnz AT 25.04.2025 B4.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 25.04.2025